Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Semax is used clinically in Russia for ischemic stroke and cognitive disorders; in models it improves learning, protects dopaminergic neurons, and modulates stress responses without significant endocrine ACTH-like effects166174.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), that is an analog of ACTH(4–10) with a Pro-Gly-Pro extension and exerts neurotrophic and neuroprotective actions partly via upregulation of BDNF and modulation of dopaminergic and glutamatergic systems40162165174.
Liraglutide is 31 amino acids long, whereas Semax is shorter as it has a length of 7 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. Semax is made up of a sequence of Methionine, Glutamic acid, Histidine, Phenylalanine, Proline, Glycine, Proline.
Liraglutide
GCG
Semax
POMC